89bio, Inc. Announces Agreement to be Acquired by Roche
September 18, 2025 01:02 ET | Source: 89bio, Inc. – 89bio stockholders…
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
89bio’s pegozafermin allows for a potentially best-in-disease treatment for moderate to severe…
